Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

CYRX

CryoPort Inc

May 17 • 04:00PM ET

12.65

Dollar change -1.01
Percentage change -7.39	%

Industrials • Integrated Freight & Logistics • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF VB VBK IWO SCHA VHT VTWO DFAS

Index	RUT	P/E	-	EPS (ttm)	-2.47	Insider Own	2.31%	Shs Outstand	48.97M	Perf Week	-5.10%
Market Cap	623.14M	Forward P/E	-	EPS next Y	-1.11	Insider Trans	-7.12%	Shs Float	48.12M	Perf Month	-23.19%
Income	-120.91M	PEG	-	EPS next Q	-0.39	Inst Own	105.08%	Short Float	8.68%	Perf Quarter	-19.38%
Sales	225.03M	P/S	2.77	EPS this Y	36.26%	Inst Trans	-0.40%	Short Ratio	8.54	Perf Half Y	-4.89%
Book/sh	9.01	P/B	1.40	EPS next Y	21.31%	ROA	-11.34%	Short Interest	4.18M	Perf Year	-37.99%
Cash/sh	9.11	P/C	1.39	EPS next 5Y	-	ROE	-21.87%	52W Range	9.00 - 23.50	Perf YTD	-18.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-45.48%	ROI	-13.72%	52W High	-46.17%	Beta	1.67
Dividend TTM	-	Quick Ratio	10.22	Sales past 5Y	78.51%	Gross Margin	34.28%	52W Low	40.56%	ATR (14)	0.99
Dividend Ex-Date	-	Current Ratio	10.73	EPS Y/Y TTM	-220.05%	Oper. Margin	-31.56%	RSI (14)	31.19	Volatility	6.81% 6.58%
Employees	1170	Debt/Eq	0.88	Sales Y/Y TTM	-9.19%	Profit Margin	-53.73%	Recom	2.20	Target Price	17.89
Option/Short	Yes / Yes	LT Debt/Eq	0.87	EPS Q/Q	-172.16%	Payout	-	Rel Volume	0.70	Prev Close	13.66
Sales Surprise	-7.13%	EPS Surprise	-24.53%	Sales Q/Q	-13.09%	Earnings	May 07 AMC	Avg Volume	489.26K	Price	12.65
SMA20	-17.50%	SMA50	-22.84%	SMA200	-13.58%	Trades		Volume	343,142	Change	-7.39%

Date	Action	Analyst	Rating Change	Price Target Change
May-03-24	Downgrade	B. Riley Securities	Buy → Neutral	$22 → $19
Apr-04-24	Resumed	Jefferies	Buy	$17 → $21
Mar-13-24	Reiterated	Needham	Buy	$19 → $18
Aug-17-23	Initiated	Morgan Stanley	Equal-Weight	$16
Aug-10-23	Downgrade	Stephens	Overweight → Equal-Weight	$15
Jul-18-23	Downgrade	UBS	Buy → Neutral	$28 → $17
Jul-17-23	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Jul-13-23	Downgrade	SVB Securities	Outperform → Market Perform	$30 → $10
Jan-19-22	Upgrade	ROTH Capital	Neutral → Buy	$90
Nov-05-21	Downgrade	ROTH Capital	Buy → Neutral	$78 → $90
Oct-19-21	Resumed	B. Riley Securities	Buy	$81
Jul-16-21	Initiated	BTIG Research	Buy	$80
Mar-15-21	Initiated	UBS	Buy	$84
Mar-02-21	Resumed	Needham	Buy	$73
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$54
Jan-08-20	Initiated	Stephens	Overweight	$21
Jul-01-19	Resumed	Needham	Buy	$22
Oct-10-18	Initiated	B. Riley FBR	Buy	$22
Aug-13-18	Reiterated	Cowen	Outperform	$11 → $16
Jul-02-18	Reiterated	Needham	Buy	$11 → $19

Show Previous Ratings

May-17-24 02:33AM	Insider Sale: Director Richard Berman Sells 8,105 Shares of CryoPort Inc (CYRX) (GuruFocus.com) -7.39%
May-08-24 02:54PM	Cryoport, Inc. (NASDAQ:CYRX) Q1 2024 Earnings Call Transcript (Insider Monkey) -19.51%
04:03AM	CryoPort Inc (CYRX) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges with ... (GuruFocus.com)
May-07-24 09:56PM	CYRX Stock Earnings: CryoPort Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:18PM	CryoPort Inc (CYRX) Q1 2024 Earnings: Revenue Declines Amid Challenges, Yet Maintains Full-Year ... (GuruFocus.com)
04:08PM	Loading…
04:08PM	Cryoport Reports First Quarter 2024 Financial Results (PR Newswire)
May-03-24 10:12AM	B. Riley Downgrades Cryoport to Neutral From Buy, Adjusts Price Target to $19 From $22 (MT Newswires) -7.05%
06:41AM	B. Riley Downgrades Cryoport to Neutral From Buy, Cuts Price Target to $19 From $22 (MT Newswires)
Apr-30-24 08:30AM	Cryoport to Report First Quarter 2024 Financial Results on May 7, 2024 (PR Newswire)
Apr-25-24 10:02AM	Earnings Preview: CryoPort, Inc. (CYRX) Q1 Earnings Expected to Decline (Zacks)
Mar-13-24 09:16AM	Cryoport, Inc. (NASDAQ:CYRX) Q4 2023 Earnings Call Transcript (Insider Monkey) -11.90%
Mar-12-24 05:52PM	CryoPort Inc (CYRX) Reports Mixed Financial Results Amidst Global Challenges (GuruFocus.com)
05:30PM	CryoPort, Inc. (CYRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Feb-27-24 08:30AM	Cryoport to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 (PR Newswire) +5.95%
10:00AM	Loading…
Feb-15-24 10:00AM	Analysts Estimate CryoPort, Inc. (CYRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-13-24 09:55AM	Should You Buy CryoPort, Inc. (CYRX) After Golden Cross? (Zacks) -8.87%
Nov-27-23 08:30AM	Cryoport and NIPPON EXPRESS HOLDINGS Form Global Strategic Partnership for Temperature-Controlled Supply Chain Services (PR Newswire)
Nov-21-23 03:26PM	Consultant's Insight: Cryoport expands its cold-chain supply chain capabilities (Air Cargo World)
Nov-16-23 08:30AM	Cryoport's CRYOPDP Expands U.S. Footprint with Acquisition of Bluebird Express (PR Newswire)
Nov-09-23 05:23PM	Cryoport, Inc. (NASDAQ:CYRX) Q3 2023 Earnings Call Transcript (Insider Monkey) +10.03%
Nov-08-23 06:05PM	CryoPort Inc (CYRX) Faces Economic Headwinds but Sees Growth in Key Segments (GuruFocus.com)
04:05PM	Cryoport Reports Third Quarter 2023 Financial Results (PR Newswire)
Nov-02-23 08:30AM	Cryoport Continues its Expansion in the European Market with Tec4med Lifescience GmbH Acquisition (PR Newswire)
Oct-26-23 10:02AM	Analysts Estimate CryoPort, Inc. (CYRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-25-23 08:30AM	Cryoport to Report Third Quarter 2023 Financial Results on November 8, 2023 (PR Newswire) -6.36%
Oct-12-23 08:30AM	Cryoport Inks New Multi-Year Supply Chain Solutions Agreement with Monash IVF (PR Newswire)
Oct-10-23 08:30AM	Cryoport and Cell and Gene Therapy Catapult Announce Strategic Collaboration at Stevenage Manufacturing Innovation Centre for Advancement of Cell and Gene Therapies (PR Newswire) +5.19%
Oct-09-23 04:05PM	Be The Match BioTherapies and Cryoport Partner to Accelerate the Development of Cell and Gene Therapies (PR Newswire)
Sep-14-23 08:30AM	Cryoport Receives 2023 IMAPAC Asia Pacific Cell & Gene Therapy Excellence Award (PR Newswire)
07:14AM	Loading…
Aug-10-23 07:14AM	Cryoport (CYRX) Fell 28.1% in Q2 Despite Beating Earnings Expectations (Insider Monkey)
Aug-09-23 05:30PM	CryoPort, Inc. (CYRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Cryoport Reports Second Quarter 2023 Financial Results (PR Newswire)
Aug-02-23 08:30AM	Cryoport to Report Second Quarter 2023 Financial Results on August 9, 2023 (PR Newswire)
Jul-31-23 08:53AM	Heres Why Cryoport (CYRX) Declined in Q2 (Insider Monkey)
Jul-23-23 08:17AM	Cryoport, Inc. (NASDAQ:CYRX) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
Jul-13-23 12:24PM	Trade Desk, MillerKnoll rise; CryoPort, Fastenal fall, Thursday, 7/13/2023 (AP Finance) -24.74%
11:17AM	Why Shares of Cryoport are Tumbling Thursday (Motley Fool)
Jul-12-23 04:05PM	Cryoport Announces Certain Preliminary Results for Second Quarter & Updates 2023 Revenue Expectations (PR Newswire)
12:56PM	Cryoport cuts FY guidance as Q2 revenue hurt by weaker demand; Shares sink (Investing.com)
Jun-29-23 08:39AM	IVFAustralia Selects Cryoport as Exclusive Supply Chain Solutions Provider (PR Newswire)
May-25-23 08:02AM	CryoPort (CYRX) Rose on Revenue Guidance (Insider Monkey)
May-12-23 07:15AM	Cryoport, Inc. (NASDAQ:CYRX) Screens Well But There Might Be A Catch (Simply Wall St.) -7.86%
May-04-23 06:05PM	CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Cryoport Reports First Quarter 2023 Results (PR Newswire)
Apr-27-23 10:02AM	Will CryoPort, Inc. (CYRX) Report Negative Q1 Earnings? What You Should Know (Zacks)
08:30AM	Cryoport to Report First Quarter 2023 Financial Results on May 4, 2023 (PR Newswire)
Apr-25-23 08:30AM	Cryoport Signs New Supply Chain Solutions Agreement with Boston IVF to Support Reproductive Material Shipments Across the U.S. (PR Newswire) -6.78%
Apr-01-23 08:54AM	Cryoport, Inc.'s (NASDAQ:CYRX) Intrinsic Value Is Potentially 94% Above Its Share Price (Simply Wall St.)
Mar-28-23 08:30AM	Cryoport Announces Multi-Year Agreement with Inception Fertility (PR Newswire)
Mar-16-23 03:46AM	Macroeconomic Headwinds Dragged Cryoport (CYRX) in Q4 (Insider Monkey) +8.28%
Mar-13-23 06:00AM	Cryoport Confirms No Financial Exposure to Silicon Valley Bank (PR Newswire)
Mar-08-23 01:15PM	Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company A Uniquely Positioned Ticker In The Weeds? (News Direct)
Feb-23-23 06:40PM	CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Cryoport Reports Fourth Quarter and Full Year 2022 Results (PR Newswire)
Feb-15-23 08:30AM	Cryoport to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023 (PR Newswire) +6.85%
Jan-29-23 07:31AM	When Will Cryoport, Inc. (NASDAQ:CYRX) Become Profitable? (Simply Wall St.)
Jan-26-23 10:55AM	Syneos Health (SYNH) Signs New Partnership With Cryoport (Zacks)
Jan-18-23 08:30AM	Cryoport Announces New Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies (PR Newswire)
Dec-20-22 08:30AM	Cryoport to Present at the J.P. Morgan 41st Annual Healthcare Conference (PR Newswire)
Dec-19-22 07:15AM	Cryoport (NASDAQ:CYRX) shareholders have earned a 15% CAGR over the last five years (Simply Wall St.) -5.30%
Nov-08-22 06:56AM	Cryoport Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-07-22 08:10PM	Time to Bottom Fish? 2 Strong Buy Stocks That Are Down 70% This Year (TipRanks)
05:03AM	Some Cryoport, Inc. (NASDAQ:CYRX) Analysts Just Made A Major Cut To Next Year's Estimates (Simply Wall St.)
Nov-03-22 06:45PM	CryoPort, Inc. (CYRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Cryoport Reports Results for the Third Quarter 2022 (PR Newswire)
Oct-27-22 08:30AM	Cryoport to Report Third Quarter 2022 Financial Results on November 3, 2022 (PR Newswire)
05:32AM	CryoPort, Inc. (CYRX) Stock Jumps 10.5%: Will It Continue to Soar? (Zacks)
Sep-08-22 08:30AM	Cryoport Enters into Strategic Relationship with Takeda's BioLife Plasma Services (PR Newswire)
Aug-08-22 02:42PM	Cryoport Stock Shows Market Leadership With Jump To 91 RS Rating (Investor's Business Daily) +6.83%
Aug-06-22 10:18AM	Cryoport, Inc.'s (NASDAQ:CYRX) Profit Outlook (Simply Wall St.)
Aug-05-22 09:55AM	Can CryoPort, Inc. (CYRX) Climb 36% to Reach the Level Wall Street Analysts Expect? (Zacks) +6.69%
Aug-04-22 07:15PM	CryoPort, Inc. (CYRX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Cryoport Reports Results for the Second Quarter 2022 (PR Newswire)
Jul-28-22 08:30AM	Cryoport to Report Second Quarter 2022 Financial Results on August 4, 2022 (PR Newswire)
Jul-01-22 08:57AM	Cryoport's (NASDAQ:CYRX) growing losses don't faze investors as the stock ascends 4.2% this past week (Simply Wall St.)
May-05-22 07:05PM	CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.97%
04:05PM	Cryoport Reports First Quarter 2022 Results (PR Newswire)
Apr-28-22 08:30AM	Cryoport to Report First Quarter 2022 Financial Results on May 5, 2022 (PR Newswire)
Apr-20-22 05:59PM	CEO: Life sciences logistics firm eyes future growth in Houston, Central Texas markets (American City Business Journals)
Apr-19-22 12:24PM	Cryoport, Cryogene growing Houston presence with new supply chain, logistics facility (American City Business Journals)
Apr-18-22 03:11PM	Cryoport pays nearly $7 million for France-based Cell&Co BioServices (American City Business Journals)
08:30AM	Cryoport Acquires Cell&Co BioServices (PR Newswire)
Mar-30-22 05:00PM	Cryoport's MVE Biological Solutions' New Prague Manufacturing Plant Returns to Full Production (PR Newswire)
Mar-11-22 03:40PM	Cryoport Authorizes $100 Million Repurchase Program (PR Newswire) -7.18%
Feb-24-22 06:30PM	CryoPort, Inc. (CYRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Cryoport Reports Fourth Quarter and Full Year 2021 Results (PR Newswire)
Feb-23-22 10:00AM	Here's Why CryoPort, Inc. (CYRX) is Poised for a Turnaround After Losing 22.8% in 4 Weeks (Zacks)
Feb-17-22 03:02PM	CryoPort, Inc. (CYRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks) -5.37%
Feb-15-22 08:30AM	Cryoport Report's Fourth Quarter and 2021 Financial Results on February 24, 2022 (PR Newswire)
Feb-09-22 09:29AM	Cryoport Provides Positive Update on MVE Biological Solution's New Prague Facility (PR Newswire) +5.11%
Feb-08-22 09:38AM	abrdn plc Buys Coca-Cola Co, Globant SA, Stanley Black & Decker Inc, Sells JPMorgan Chase, ... (GuruFocus.com)
Feb-01-22 05:38PM	First Bank & Trust Buys Daktronics Inc, Amgen Inc, Bristol-Myers Squibb Co, Sells Pfizer ... (GuruFocus.com)
Jan-31-22 05:35PM	Cryoport Reports Fire Damage at MVE's New Prague Facility (PR Newswire) +11.33%
Jan-28-22 05:46AM	Does Cryoport (NASDAQ:CYRX) Have A Healthy Balance Sheet? (Simply Wall St.)
Jan-27-22 08:30AM	Cryoport and Cell Matters Enter into Strategic Partnership (PR Newswire) -7.46%
Jan-26-22 05:38PM	Howland Capital Management Llc Buys PIMCO Dynamic Income Fund, PayPal Holdings Inc, iShares ... (GuruFocus.com) -8.07%
Jan-21-22 05:38PM	Rheos Capital Works Inc. Buys EOG Resources Inc, Tesla Inc, Wheaton Precious Metals Corp, Sells ... (GuruFocus.com)
09:38AM	Harvest Group Wealth Management, Llc Buys Real Estate Select Sector SPDR Fund (The), iShares ... (GuruFocus.com)
Jan-05-22 01:38PM	Spence Asset Management Buys CryoPort Inc, Silvergate Capital Corp, Vanguard Total ... (GuruFocus.com) -8.44%

CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Brentwood, TN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BERMAN RICHARD J	Director	May 15 '24	Sale	13.41	8,105	108,693	100,000	May 16 05:30 PM
ZECCHINI EDWARD J	Chief Digital and Tech Officer	May 14 '24	Sale	13.37	3,443	46,042	60,051	May 15 07:28 PM
SHELTON JERRELL	Chief Executive Officer	Mar 25 '24	Sale	17.54	2,631	46,154	692,182	Mar 26 08:09 PM
Sawicki Mark W	Chief Scientific Officer	Mar 25 '24	Sale	17.54	1,367	23,980	77,444	Mar 26 08:08 PM
STEFANOVICH ROBERT	Chief Financial Officer	Mar 25 '24	Sale	17.54	1,079	18,928	128,333	Mar 26 08:12 PM
SHELTON JERRELL	President, CEO	Mar 15 '24	Option Exercise	4.80	100,000	480,000	749,253	Mar 19 07:48 PM
Mandalam Ramkumar	Director	Mar 15 '24	Option Exercise	5.40	8,334	45,004	46,404	Mar 19 07:49 PM
BADDOUR LINDA	Director	Mar 15 '24	Option Exercise	0.00	1,111	0	21,690	Mar 19 07:48 PM
SHELTON JERRELL	President, CEO	Mar 15 '24	Sale	15.30	57,039	872,884	634,352	Mar 19 07:48 PM
Mandalam Ramkumar	Director	Mar 15 '24	Sale	14.68	3,217	47,226	43,187	Mar 19 07:49 PM
Sawicki Mark W	Chief Scientific Officer	Mar 15 '24	Sale	15.43	1,312	20,247	73,061	Mar 19 07:50 PM
STEFANOVICH ROBERT	Chief Financial Officer	Mar 15 '24	Sale	15.43	1,035	15,972	123,662	Mar 19 07:51 PM
SHELTON JERRELL	President, CEO	Mar 11 '24	Sale	16.35	3,723	60,880	636,951	Mar 19 07:48 PM
Sawicki Mark W	Chief Scientific Officer	Mar 11 '24	Sale	16.35	1,418	23,188	74,373	Mar 19 07:50 PM
STEFANOVICH ROBERT	Chief Financial Officer	Mar 11 '24	Sale	16.35	1,119	18,298	124,697	Mar 19 07:51 PM
STEFANOVICH ROBERT	Chief Financial Officer	Mar 09 '24	Option Exercise	0.00	2,666	0	125,816	Mar 19 07:51 PM
SHELTON JERRELL	President, CEO	Mar 09 '24	Option Exercise	0.00	8,250	0	640,674	Mar 19 07:48 PM
Sawicki Mark W	Chief Scientific Officer	Mar 09 '24	Option Exercise	0.00	2,666	0	75,791	Mar 19 07:50 PM
Hariri Robert J	Director	Dec 14 '23	Sale	16.89	800	13,512	12,716	Dec 18 07:19 PM
Hariri Robert J	Director	Dec 11 '23	Sale	15.50	1,000	15,500	13,516	Dec 13 06:02 PM
Sawicki Mark W	Chief Scientific Officer	Sep 12 '23	Option Exercise	12.79	1,000	12,790	73,125	Sep 13 05:01 PM
Hariri Robert J	Director	Sep 06 '23	Sale	13.60	1,500	20,400	14,516	Sep 12 06:01 PM
SHELTON JERRELL	See Remarks	Sep 01 '23	Option Exercise	1.87	54,000	100,980	659,299	Sep 05 05:53 PM
SHELTON JERRELL	See Remarks	Sep 01 '23	Sale	14.27	26,875	383,407	632,424	Sep 05 05:53 PM
STEFANOVICH ROBERT	Chief Financial Officer	Aug 29 '23	Option Exercise	3.07	16,000	49,120	123,150	Aug 30 05:30 PM

Open in Screener

CELU

Celularity Inc

May 17 • 04:00PM ET

3.00

Dollar change -0.05
Percentage change -1.64	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF DFAC

Index	-	P/E	-	EPS (ttm)	-5.50	Insider Own	51.56%	Shs Outstand	21.78M	Perf Week	1.69%
Market Cap	65.34M	Forward P/E	-	EPS next Y	-	Insider Trans	190.66%	Shs Float	10.55M	Perf Month	-6.54%
Income	-181.41M	PEG	-	EPS next Q	-	Inst Own	14.28%	Short Float	5.64%	Perf Quarter	-30.88%
Sales	14.79M	P/S	4.42	EPS this Y	-	Inst Trans	377.53%	Short Ratio	8.09	Perf Half Y	49.18%
Book/sh	1.56	P/B	1.92	EPS next Y	-	ROA	-61.05%	Short Interest	0.59M	Perf Year	-43.40%
Cash/sh	0.01	P/C	242.00	EPS next 5Y	-	ROE	-186.56%	52W Range	1.59 - 8.90	Perf YTD	21.26%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-322.10%	52W High	-66.29%	Beta	0.44
Dividend TTM	-	Quick Ratio	0.14	Sales past 5Y	-	Gross Margin	-42.83%	52W Low	88.68%	ATR (14)	0.39
Dividend Ex-Date	-	Current Ratio	0.19	EPS Y/Y TTM	-628.37%	Oper. Margin	-658.47%	RSI (14)	41.43	Volatility	15.17% 11.46%
Employees	-	Debt/Eq	2.02	Sales Y/Y TTM	-20.93%	Profit Margin	-1226.72%	Recom	1.00	Target Price	25.00
Option/Short	Yes / Yes	LT Debt/Eq	0.86	EPS Q/Q	-15726.96%	Payout	-	Rel Volume	0.45	Prev Close	3.05
Sales Surprise	-7.71%	EPS Surprise	118.07%	Sales Q/Q	-8.44%	Earnings	-	Avg Volume	73.52K	Price	3.00
SMA20	-3.52%	SMA50	-30.61%	SMA200	-6.31%	Trades		Volume	32,761	Change	-1.64%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$5 → $1
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Jun-22-22	Initiated	H.C. Wainwright	Buy	$15
Apr-06-22	Downgrade	Truist	Buy → Hold	$10
Jan-28-22	Initiated	Oppenheimer	Outperform	$9
Nov-24-21	Initiated	Morgan Stanley	Equal-Weight	$9

May-14-24 09:15AM	Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy (GlobeNewswire) +25.95%
Apr-22-24 08:00AM	Celularity Inc. to Host Investor and Analyst Research & Development Day (GlobeNewswire)
Apr-19-24 05:30PM	Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing (GlobeNewswire) -5.61%
Apr-18-24 04:30PM	Celularity Abstract Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials Accepted at ORS Tendon Conference 2024 (GlobeNewswire)
Apr-15-24 08:00AM	Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products (GlobeNewswire)
09:00AM	Loading…
Apr-08-24 09:00AM	Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells (GlobeNewswire)
Mar-26-24 09:00AM	Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L (GlobeNewswire)
Mar-20-24 09:15AM	Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy (GlobeNewswire)
Mar-14-24 09:15AM	Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit (GlobeNewswire)
Mar-12-24 09:20AM	Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress (GlobeNewswire) -15.30%
Mar-07-24 09:35AM	Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells (GlobeNewswire) +27.67%
Feb-23-24 04:10PM	Celularity Announces 1-for-10 Reverse Stock Split (GlobeNewswire) +7.13%
Feb-14-24 04:05PM	Celularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease (GlobeNewswire)
Feb-01-24 09:00AM	Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline (GlobeNewswire) +28.45%
Jan-25-24 09:00AM	Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions (GlobeNewswire) +16.00%
01:40PM	Loading…
Jan-18-24 01:40PM	Celularity Releases CEO Letter to Shareholders (GlobeNewswire) +53.48%
Jan-04-24 01:00PM	Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare (GlobeNewswire) -9.25%
Jan-03-24 07:30PM	BioCellgraft Finalizes Commercialization Agreement with Celularity For The Manufacture and Distribution of Products for Therapeutic Use in Oral Healthcare (PR Newswire)
12:00PM	Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023 (GlobeNewswire)
Nov-24-23 01:15PM	Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing (GlobeNewswire)
Oct-18-23 09:00AM	Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification (GlobeNewswire) -8.35%
Sep-07-23 04:10PM	Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors (GlobeNewswire)
Aug-29-23 09:00AM	Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron (GlobeNewswire) +8.04%
Jul-27-23 09:07AM	Celularity Inc. Announces $3 Million Registered Direct Offering (GlobeNewswire) +9.57%
09:00AM	Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications (GlobeNewswire)
Jul-18-23 09:00AM	Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies (GlobeNewswire) +5.71%
Jun-29-23 04:05PM	Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics (GlobeNewswire) +5.89%
Jun-01-23 09:15AM	Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability (GlobeNewswire) -8.71%
May-23-23 10:56AM	CELULARITY ANNOUNCES $45 MILLION PURCHASE ORDER, FIRST MIDDLE EAST PRIVATE LABEL AGREEMENT FOR CELULARITY'S HALAL-CERTIFIED BIOMATERIAL PRODUCTS (PR Newswire)
May-19-23 04:21PM	Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohns Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation (GlobeNewswire) +11.27%
09:00AM	Loading…
May-10-23 09:00AM	Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders for Celularity Branded Halal-Certified Biomaterial Products (GlobeNewswire) +10.18%
May-01-23 04:01PM	Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell Therapy (GlobeNewswire) -8.79%
Apr-27-23 09:00AM	Celularity Announces Clinical Data on Human Placental-Derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate Cynk-001 in Adult Patients With Relapsed Refractory and Measurable Residual Disease-Positive Acute Myeloid Leukemia (GlobeNewswire)
Apr-12-23 09:00AM	Celularitys Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference Beyond Longevity: Live 120 Like 50 (GlobeNewswire)
Apr-05-23 09:00AM	Celularity Inc. Announces $6 Million Registered Direct Offering (GlobeNewswire) -11.48%
Apr-04-23 09:00AM	Celularity Announces Acceptance of Poster Presentation at 2023 Society for Biomaterials Annual Meeting (GlobeNewswire)
Apr-03-23 09:00AM	Celularity Receives U.S. Food And Drug Administration (FDA) Preliminary Assessment For Celularitys Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDAs Center For Devices And Radiological Health (GlobeNewswire) +19.41%
Mar-28-23 10:55AM	Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the GCC and Egypt (PR Newswire)
09:00AM	Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt (GlobeNewswire)
Feb-02-23 07:53AM	Correcting & Replacing -- Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) (GlobeNewswire)
Feb-01-23 04:05PM	Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) (GlobeNewswire) +8.50%
Jan-26-23 04:17PM	Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-Up and Pipeline Prioritization of Next-Generation Product Candidates (GlobeNewswire)
Jan-11-23 01:35PM	Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East (PR Newswire) +13.21%
01:22PM	Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia (PR Newswire)
Jan-06-23 08:10AM	Celularitys Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohns Disease in Phase 1, Phase 1b/2a and Phase 1b Studies (GlobeNewswire)
Jan-04-23 04:10PM	Celularity Appoints Paul Graves as Chief Communications Officer (GlobeNewswire)
Dec-05-22 08:00AM	Celularity Announces Halal Certification of its Advanced Cellular Therapeutics, Biomaterial Products and Business Model (Business Wire)
Nov-30-22 09:55AM	Celularity CEO Robert J. Hariri, M.D., Ph.D., Addresses FII Conference on "The Science and Technology for Extending Healthy Human Lifespan" (Business Wire)
Nov-10-22 05:00PM	Imugenes onCARlytics combination with Celularitys placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting (GlobeNewswire) +14.52%
04:10PM	Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
09:10AM	Celularity Presents Preclinical Data on CYNK-101, its Allogeneic Genetically-Modified Natural Killer Cell Therapy Candidate, at the Society for Immunotherapy of Cancers 37th Annual Meeting (GlobeNewswire)
Oct-06-22 08:00AM	Celularity Promotes Two Executives in Executive Leadership Team (GlobeNewswire)
Oct-03-22 08:00AM	Celularity Appoints Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical Officer (GlobeNewswire) -5.19%
Sep-27-22 08:00AM	Celularity to Present at Jefferies Cell and Genetic Medicine Summit (GlobeNewswire)
Sep-26-22 08:00AM	Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro (GlobeNewswire)
Sep-15-22 02:29PM	Celularity Enters Into $150 Million Pre-Paid Advance Agreement with Yorkville (GlobeNewswire) -8.90%
Sep-06-22 04:10PM	Celularity Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-09-22 04:10PM	Celularity Reports Second Quarter 2022 Financial Results and Corporate Update (GlobeNewswire)
Jul-27-22 08:00AM	Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers (GlobeNewswire) -10.89%
Jul-04-22 10:08AM	Celularity (NASDAQ:CELU) shareholders have endured a 65% loss from investing in the stock a year ago (Simply Wall St.)
Jun-08-22 04:10PM	Celularity To Be Added To The Russell 3000® Index And The Small-Cap Russell 2000® (GlobeNewswire)
Jun-03-22 08:00AM	Celularity Appoints Industry Leader Diane Parks to its Board of Directors (GlobeNewswire)
May-18-22 08:30AM	Celularity Inc. Announces $30 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
May-16-22 04:10PM	Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -12.53%
Mar-31-22 04:05PM	Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-15-22 04:05PM	Celularity to Present at Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire)
12:59PM	What Percentage Of Celularity Inc. (NASDAQ:CELU) Shares Do Insiders Own? (Simply Wall St.)
Feb-15-22 04:05PM	Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers (GlobeNewswire) +8.36%
Jan-27-22 05:38PM	C V Starr & Co Inc Buys Celularity Inc (GuruFocus.com) -6.47%
05:38PM	Starr International Co Inc Buys Celularity Inc, Sells Moderna Inc, AstraZeneca PLC, Johnson ... (GuruFocus.com)
Jan-18-22 08:00AM	Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers (GlobeNewswire) -7.97%
Dec-27-21 08:00AM	Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML (GlobeNewswire) +6.60%
Dec-15-21 09:04AM	Analysts' Revenue Estimates For Celularity Inc. (NASDAQ:CELU) Are Surging Higher (Simply Wall St.)
Dec-13-21 08:00AM	Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition (GlobeNewswire) -7.61%
Nov-29-21 08:00AM	Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer (GlobeNewswire)
Nov-16-21 05:35AM	Celularity (NASDAQ:CELU) investors are sitting on a loss of 34% if they invested a year ago (Simply Wall St.) +5.73%
Nov-15-21 08:00AM	Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the Society for Immunotherapy of Cancer 36th Annual Meeting (GlobeNewswire)
Nov-12-21 04:05PM	Celularity Reports Third Quarter 2021 Financial Results and Corporate Update (GlobeNewswire)
Sep-20-21 08:00AM	Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies (GlobeNewswire)
08:00AM	Celularity and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies (GlobeNewswire)
Aug-16-21 05:15PM	Celularity Reports Second Quarter 2021 Financial Results (GlobeNewswire) -5.38%
Aug-04-21 07:00PM	Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus - Allogeneic CAR T-Cell Immunotherapy Combination for the Treatment of Solid Tumors (GlobeNewswire)

Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lim Kok Thay	10% Owner	Jan 12 '24	Buy	0.25	21,410,983	5,331,335	51,473,762	Jan 17 05:22 PM
Hariri Robert J	Chief Executive Officer	Oct 05 '23	Buy	0.16	9,357,585	1,484,113	28,570,434	Oct 10 09:48 PM
Hariri Robert J	Chief Executive Officer	Sep 29 '23	Buy	0.17	9,064,539	1,500,181	19,212,849	Oct 10 09:48 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

CYRX

CryoPort Inc

CELU

Celularity Inc

Upgrade your FINVIZ experience